Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 12, 2020

SELL
$37.02 - $51.28 $25,914 - $35,896
-700 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$43.24 - $55.02 $30,268 - $38,514
700 New
700 $34,000
Q3 2019

Nov 12, 2019

SELL
$53.25 - $59.98 $407,256 - $458,727
-7,648 Closed
0 $0
Q2 2019

Aug 12, 2019

SELL
$46.61 - $58.45 $176,605 - $221,467
-3,789 Reduced 33.13%
7,648 $426,000
Q1 2019

May 15, 2019

SELL
$38.66 - $51.82 $381,303 - $511,100
-9,863 Reduced 46.31%
11,437 $577,000
Q4 2018

Feb 06, 2019

SELL
$36.72 - $67.73 $470,016 - $866,944
-12,800 Reduced 37.54%
21,300 $858,000
Q3 2018

Nov 09, 2018

BUY
$66.65 - $83.86 $2.19 Million - $2.75 Million
32,800 Added 2523.08%
34,100 $2.36 Million
Q2 2018

Aug 07, 2018

BUY
$51.25 - $76.62 $66,625 - $99,606
1,300 New
1,300 $98,000

Others Institutions Holding EGRX

About EAGLE PHARMACEUTICALS, INC.


  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $7.81M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Canada Pension Plan Investment Board Portfolio

Follow Canada Pension Plan Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Canada Pension Plan Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on Canada Pension Plan Investment Board with notifications on news.